The IGF-1R/AKT Pathway Has Opposing Effects on Nutlin-3a-induced Apoptosis

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2017 Jul 12

PMID 28696156

Citations 7

Authors

Batzaya Davaadelger

Ricardo E Perez

Yalu Zhou

Lei Duan

Steven Gitelis

Carl G Maki

Affiliations

Soon will be listed here.

Abstract

Nutlin-3a is a small molecule MDM2 antagonist and potent activator of wild-type p53. Nutlin-3a disrupts MDM2 binding to p53, thus increasing p53 levels and allowing p53 to inhibit proliferation or induce cell death. Factors that control sensitivity to Nutlin-3a-induced apoptosis are incompletely understood. In this study we isolated cisplatin-resistant clones from MHM cells, an MDM2-amplified and p53 wild-type osteosarcoma cell line. Cisplatin resistance in these clones resulted in part from heightened activation of the IGF-1R/AKT pathway. Interestingly, these cisplatin resistant clones showed hyper-sensitivity to Nutlin-3a induced apoptosis. Increased Nutlin-3a sensitivity was associated with reduced authophagy flux and a greater increase in p53 levels in response to Nutlin-3a treatment. IGF-1R and AKT inhibitors further increased apoptosis by Nutlin-3a in parental MHM cells and the cisplatin-resistant clones, confirming IGF-1R/AKT signaling promotes apoptosis resistance. However, IGF-1R and AKT inhibitors also reduced p53 accumulation in Nutlin-3a treated cells and increased autophagy flux, which we showed can promote apoptosis resistance. We conclude the IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. First, it can inhibit apoptosis, consistent with its well-established role as a survival-signaling pathway. Second, it can enhance Nutlin-3a induced apoptosis through a combination of maintaining p53 levels and inhibiting pro-survival autophagy.

Citing Articles

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?.

Haronikova L, Bonczek O, Zatloukalova P, Kokas-Zavadil F, Kucerikova M, Coates P Cell Mol Biol Lett. 2021; 26(1):53.

PMID: 34911439 PMC: 8903693. DOI: 10.1186/s11658-021-00293-6.

The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease.

Zhou C, Duan S Cancers (Basel). 2020; 12(11).

PMID: 33113895 PMC: 7690676. DOI: 10.3390/cancers12113086.

MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies.

Roy S, Laroche-Clary A, Verbeke S, Derieppe M, Italiano A Cancers (Basel). 2020; 12(8).

PMID: 32806555 PMC: 7465494. DOI: 10.3390/cancers12082253.

Identification of Kinases Responsible for p53-Dependent Autophagy.

Celano S, Yco L, Kortus M, Solitro A, Gunaydin H, Scott M iScience. 2019; 15:109-118.

PMID: 31048145 PMC: 6495467. DOI: 10.1016/j.isci.2019.04.023.

Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.

Li C, Zhang S, Qiu T, Wang Y, Ricketts D, Qi C Cancer Biol Ther. 2018; 20(4):413-422.

PMID: 30489194 PMC: 6422455. DOI: 10.1080/15384047.2018.1538612.

References

Laptenko O, Prives C . Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006; 13(6):951-61. DOI: 10.1038/sj.cdd.4401916. View

Denduluri S, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed M . Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015; 2(1):13-25. PMC: 4431759. DOI: 10.1016/j.gendis.2014.10.004. View

Boehme K, Kulikov R, Blattner C . p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A. 2008; 105(22):7785-90. PMC: 2409394. DOI: 10.1073/pnas.0703423105. View

Abedini M, Muller E, Bergeron R, Gray D, Tsang B . Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene. 2009; 29(1):11-25. DOI: 10.1038/onc.2009.300. View

Zhang X, Tang N, Hadden T, Rishi A . Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011; 1813(11):1978-86. DOI: 10.1016/j.bbamcr.2011.03.010. View

Davaadelger B, Duan L, Perez R, Gitelis S, Maki C . Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016; 7(19):27511-26. PMC: 5053668. DOI: 10.18632/oncotarget.8484. View

Russell R, Yuan H, Guan K . Autophagy regulation by nutrient signaling. Cell Res. 2013; 24(1):42-57. PMC: 3879708. DOI: 10.1038/cr.2013.166. View

Vadysirisack D, Baenke F, Ory B, Lei K, Ellisen L . Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol. 2011; 31(21):4356-65. PMC: 3209328. DOI: 10.1128/MCB.05541-11. View

Huang J, Dibble C, Matsuzaki M, Manning B . The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008; 28(12):4104-15. PMC: 2423120. DOI: 10.1128/MCB.00289-08. View

10.

Hay N . p53 strikes mTORC1 by employing sestrins. Cell Metab. 2008; 8(3):184-5. PMC: 5744681. DOI: 10.1016/j.cmet.2008.08.010. View

11.

Huang B, Deo D, Xia M, Vassilev L . Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res. 2009; 7(9):1497-509. DOI: 10.1158/1541-7786.MCR-09-0144. View

12.

Vousden K, Prives C . Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-31. DOI: 10.1016/j.cell.2009.04.037. View

13.

Goetz E, Shankar B, Zou Y, Morales J, Luo X, Araki S . ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene. 2011; 30(35):3745-54. PMC: 4807730. DOI: 10.1038/onc.2011.92. View

14.

Pene F, Claessens Y, Muller O, Viguie F, Mayeux P, Dreyfus F . Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002; 21(43):6587-97. DOI: 10.1038/sj.onc.1205923. View

15.

Kubbutat M, Jones S, Vousden K . Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630):299-303. DOI: 10.1038/387299a0. View

16.

Shen H, Maki C . Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010; 285(30):23105-14. PMC: 2906304. DOI: 10.1074/jbc.M110.124990. View

17.

Werner H, Karnieli E, Rauscher F, LeRoith D . Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A. 1996; 93(16):8318-23. PMC: 38668. DOI: 10.1073/pnas.93.16.8318. View

18.

Saiki A, Caenepeel S, Yu D, Lofgren J, Osgood T, Robertson R . MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways. Oncotarget. 2014; 5(8):2030-43. PMC: 4039142. DOI: 10.18632/oncotarget.1918. View

19.

Parcellier A, Tintignac L, Zhuravleva E, Hemmings B . PKB and the mitochondria: AKTing on apoptosis. Cell Signal. 2007; 20(1):21-30. DOI: 10.1016/j.cellsig.2007.07.010. View

20.

ODay K, Gorlick R . Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009; 9(4):511-23. DOI: 10.1586/era.09.7. View